Clinical trial · Observational
Oncoliq: Test for Early Breast Cancer Detection.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs. To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity. Currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncoliq: test for early breast cancer detection. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PPHM-0000-21
- description
- 50-70 year old female patients, without a personal history of oncological pathology, who attend for gynecological and mammographic control.
- interventionNames
- Diagnostic Test: Oncoliq: test for early breast cancer detection.
Primary outcomes (1)
- measure
- miRNA levels in plasma
- timeFrame
- Day 1
- description
- miRNA levels in plasma will be determined by RT-qPCR.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Women patients performing gynecological control * Between 50-70 years old * Without personal history of oncological disease * Informed consent signed Exclusion Criteria: * Patients who don´t meet the inclusion criteria. * Active infection with SARS-CoV-2 (COVID-19).
References
Publications (0)
Data not yet available